Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada
Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing, and commercialization of plant-derived
cannabinoid-based products, is pleased to announce the launch of
re+PLAY sports recovery-based CBD brand through partnership with
Harrington Wellness, founded by NBA veteran Al Harrington.
A photo accompanying this announcement is available at
re+PLAY is a performance-based CBD wellness
brand built with the fundamentals and combined knowledge of
scientists, athletes, doctors, and certified athletic
trainers. Avicanna and Harrington Wellness have worked
together rigorously on the research, development, and optimization
of these CBD-based topicals inspired by the athletic and sports
community. These CBD-based topicals utilize Avicanna’s proprietary
and evidence-based deep tissue technology for cannabinoid delivery
and have been curated with the support of Harrington Wellness’ deep
understanding of the needs of professional athletes.
“We're very excited to work with our partners at Avicanna to
bring our powerful line of performance recovery based topicals to
Canada,” stated Al Harrington, CEO of Harrington Wellness.
The products are now available across adult use
channels in Alberta and expected to launch Q1 2022 in Ontario and
other provinces. Additionally, the products will be made available
to patients through medical channels in partnership with Medical
Cannabis by Shoppers nationwide in early January as well.
“We are thrilled to be expanding our wellness
product offerings within the Canadian marketplace and to be
introducing the first sports focused THC-Free line of functional
products. This line has been curated through this world class
partnership with the Harrington Wellness team and been in
development since 2019.”
Initial product offerings
Rub - A water-based emulsion that combines 500 mg of pure
Cannabidiol (CBD) with complementary natural active ingredients
including menthol, camphor, and the terpene beta-caryophyllene. The
intense formulation offers a warming sensation upon application and
is formulated to enhance delivery into deeper layers of skin.
Body Cream - A water-based emulsion that combines 250 mg
of pure CBD with complementary natural active ingredients including
menthol, beta-caryophyllene and eucalyptus essential oil for an
immediate cooling sensation with a light scent.
- Foot +
Ankle Cream - A rich cream that combines 500 mg of pure
CBD with soothing colloidal oatmeal as well as antimicrobial tea
tree and spearmint essential oils to provide a cool but gentle
sensation on feet. This fast-absorbing, lightly scented cream is
formulated to enhance delivery into deeper layers of skin.
About re+PLAYre+PLAY is a
performance and recovery-based CBD brand that delivers the natural
and powerful benefits of CBD through advanced formulations that
have undergone extensive research and development to meet the
quality and consistency standards that athletes and physicians can
be confident in. The line is THC-Free and endorsed by doctors and
used by both professional athletes and certified athletic trainers.
re+PLAY was founded by NBA Veteran Al Harrington, renown trainer
Joe Abunasser and Dr. Sanford Kunkel, the team physician for both
the Indiana Pacers and the USA national basketball team.
About AvicannaAvicanna is a
Canadian commercial-stage biopharmaceutical company established in
cannabinoid research, development, and evidence-based products for
the global consumer, as well as medical and pharmaceutical market
segments. In leading global cannabinoid advancements, Avicanna
conducts most of its research in Canada at its R&D headquarters
in the Johnson & Johnson Innovation Centre, JLABS @ Toronto,
located in the MaRS Discovery District. The company actively
collaborates with leading Canadian academic and medical
institutions. Avicanna has established an industry-leading
scientific platform including advanced R&D and clinical
development which has led to the commercialization of over twenty
products across four main market segments:
- Medical Cannabis
& Wellness Products: Marketed under the RHO Phyto™ brand, or
Magisterial Preparations, these medical and wellness products are
an advanced line of pharmaceutical-grade cannabis products
containing varying ratios of cannabidiol (“CBD”) and
tetrahydrocannabinol (“THC”). The product portfolio contains a full
formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The advanced formulary is marketed with consumer, patient and
medical community education and training. Avicanna’s medical and
wellness product portfolio also forms the foundation of the
Company’s pharmaceutical pipeline with the contribution of the
formulations that form the basis of the products as well as the
data generated from sales and participation of the products in real
world evidence studies.
Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura
Earth™ brands, these registered, clinically tested, derma-cosmetic
products include a portfolio of functional CBD topical
Pipeline: Leveraging Avicanna’s scientific platform, vertical
integration, and real-world evidence, Avicanna has created a
pipeline of patent-pending drug candidates which are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates
provide solutions for unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox) is in the
drug registration stage in South America.
- Cannabis Raw
Materials, Seeds, and Bulk Formulations: Marketed under the Aureus™
brand, the Company’s raw material business has successfully
completed sales to 11 countries. Aureus offers cannabis dried
flower, standardized seeds, full spectrum extracts, and cannabinoid
distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”)
and other rare cannabinoids), and bulk formulations derived from
hemp and cannabis cultivars through its sustainable, economical,
and industrial-scale subsidiaries based in Colombia. The majority
of the Aureus products are produced at Santa Marta Golden Hemp
S.A.S. (“SMGH”), the Company’s majority-owned subsidiary, which is
also Good Agricultural and Collection Practices (“GACP”) certified
and has United States Department of Agriculture (“USDA”) National
Organic Program certification for its hemp cultivar.
SOURCE Avicanna Inc.
Stay ConnectedFor more information about
Avicanna, visit www.avicanna.com, contact Ivana Maric by email at
email@example.com or follow us on social media on LinkedIn,
Twitter, Facebook or Instagram.
The Company posts updates through videos from the official
company YouTube channel
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking
information" within the meaning of applicable securities laws.
Forward-looking information contained in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions. Forward-looking information is not a
guarantee of future performance and is based upon a number of
estimates and assumptions of management in light of management's
experience and perception of trends, current conditions and
expected developments, as well as other factors relevant in the
circumstances, including assumptions in respect of current and
future market conditions, the current and future regulatory
environment, the availability of licenses, approvals and permits,
and the utility and application of certain drugs and products.
Although the Company believes that the expectations and assumptions
on which such forward looking information is based are reasonable,
undue reliance should not be placed on the forward looking
information because the Company can give no assurance that they
will prove to be correct. Actual results and developments may
differ materially from those contemplated by these statements.
Forward-looking information is subject to a variety of risks and
uncertainties that could cause actual events or results to differ
materially from those projected in the forward-looking information.
Such risks and uncertainties include, but are not limited to
current and future market conditions, including the market price of
the common shares of the Company, and the risk factors set out in
the Company's annual information form dated September 3, 2021 and
final short form prospectus dated November 27, 2020, filed with the
Canadian securities regulators and available under the Company's
profile on SEDAR at www.sedar.com. The statements in this press
release are made as of the date of this release. The Company
disclaims any intent or obligation to update any forward-looking
information, whether as a result of new information, future events
or results or otherwise, other than as required by applicable
Historical Stock Chart
From May 2022 to Jun 2022
Historical Stock Chart
From Jun 2021 to Jun 2022